Clinical equivalence between salbutamol hydrofluoroalkane pMDI and salbutamol TurbuhalerTM at the same cumulative microgram doses in paediatric patients  by GUSTAFSSON, P et al.
Vol.96 (2002) 957^959CASEREPORT
Clinical equivalence between salbutamol
hydro£uoroalkane pMDI and salbutamol
TurbuhalerTM at the same cumulativemicrogram
doses in paediatric patients
P.GUSTAFSSON*, S.K(LLMAN* AND P. J.WHITEHEADw
*Department of Paediatrics,Central Hospital, Sk˛vde, Sweden, wGlaxoSmithKline Research and Development,
Uxbridge,Middlesex,U.K.
Abstract This study aimed to demonstrate equivalent efficacy and safety between salbutamol delivered via the
HFA134a pMDI (Hydrofluoroalkane134a pressurised Metered Dose Inhaler) and theTurbuhalertdrypowder inhaler in
asthmaticchildren.Thiswas a randomised, double-blind, double-dummy, placebo-controlled, crossover studyin10 asth-
matic children aged 6^15 years who demonstrated at least10% reversibility of FEV1after inhaling 400 mg of salbutamol.
On 5 single studydays subjects received either placebo orcumulative doses of100, 200,400 and 800 mgof salbutamol at
30minuteintervals.Bothdeviceswereplaceboonone studyday,while eachdevicewasactiveontwostudydays.FEV1was
measuredbefore and 20minutes aftereachdose.Heartratewasmeasuredbefore spirometry.Mean FEV1andheartrate
ateachtimepoint andthe areaunder the doseresponsetime curve (AUC)were analysedusing ANOVA.FEV1increased
similarlyaftercumulative doses of salbutamoloneachofthe studydays, irrespective ofdevice.Meantreatmentdifference
inAUCwas 0.01L.min (95%CI ^0.05 to 0.08L).Heartdidnotdiffer at anydose.Itisconcludedthat salbutamoldelivery from
aHFApMDIand Turbuhalertis equivalentonamicrogrambasisin asthmaticchildrenforefficacyandsafety.r2002 Elsevier
Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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The pressurised Metered-dose inhaler (pMDI) is the
mostcommonlyusedmetered-dose inhaler. Traditionally
formulated with CFCs, it is now available with a new
CFC-free propellant, hydro£uoroalkane 134a (HFA).
Some patients (including the elderly and very young)
can have di⁄culties in co-ordinating the use of pMDIs,
but this can be largely overcome by using a spacer or
using a breath-activated dry powder inhaler (DPI) in-
stead (1).
Some DPIs (such as theTurbuhalert (TH)FTurbuha-
lert is a trademark of AstraZeneca Pharmaceuticals.)Received13 November 2001, accepted in revised form 20March 2002
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E-mail: pmgmed@artech.sehave been claimed to give better drug deposition in the
lungs than the pMDI, resulting in higher e⁄cacy (2,3).
Data in adults have shown equivalent e⁄cacy and safety
between salbutamol delivered via the HFA pMDI or the
TH (4), however, and the aim of the current study was to
assess this in paediatrics.
METHODS
Ten children aged 6^15 years (mean12 years) with a his-
tory of asthma,X10% reversibility from baseline in FEV1
after inhaling 400mg of salbutamol and demonstrated
ability to usebothdevices,were enrolled into thisrando-
mised, double-blind, double-dummy, placebo-controlled,
crossover study. Prior to enrolment the subjects’ legal
guardians gavewritten informed consent for their parti-
cipation and the subjects gave their assent.
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FIG. 1. Increase in FEV1after cumulative dosing.
958 RESPIRATORYMEDICINEOn 5 single study days, subjects received either place-
bo or cumulative doses of100, 200,400 and 800mgof sal-
butamol at 30min intervals. On each dosing occasion,
they inhaled from both devices (according to the stan-
dard instructions suppliedby themanufacturers) and re-
ceived either an HFA pMDI (100mg/actuation) and TH
placebo, aTH (100mg/actuation) and HFA pMDI placebo,
or placebo fromboth devices.Both deviceswereplacebo
on 1 study day, while each device was active on 2 study
days, the data fromwhichwere then combined for analy-
sis to minimise variability. Dosing started at the same
time on each studyday (71h) and the dayswere at least
46h apart to avoid any carry-over e¡ects.FEV1wasmea-
suredusing a turbine spirometer before and 20min after
each dose for three times on each occasion, and thehigh-
est value noted.The spirometer was checked daily using
a 3 l precision syringe. Heart rate was measured before
spirometry over 1min using a stethoscope. Before dos-
ing, subjects had to havewithheld from taking short-act-
ing b2-agonists for 6h and long-acting b2-agonists for
12h, and have a baseline FEV1 within 715% of their
screening value.
The study was designed to show equivalence between
the HFA pMDI and TH, de¢ned as the 95% con¢dence
intervals (95% CI) for the mean treatment di¡erence
being within 70.25 l for FEV1 and 78 beats/min (bpm)
for heart rate. Analysis of themean FEV1and heart rate
at each time point and the area under the dose response
time curve (AUC)wasperformedusing analysis of covar-
iance, allowing for e¡ects due to subjects, periods, pre-
dosing values and treatments.
RESULTS
FEV1
FEV1 increased similarly after cumulative doses of salbu-
tamol on each of the study days, irrespective of delivery
device (Fig. 1). The adjusted mean treatment di¡erence
between the HFA pMDI and TH was well within the
equivalence criteria at each dose, e.g. after100mg it was
0.02 l (95% CI0.05 to 0.09 l), and after 800mg was 0.04l
(95% CI0.05 to 0.12l).Themean treatment di¡erence in
the AUCwas 0.01l.min (95% CI0.05 to 0.08 l). Both de-
vices were signi¢cantly better than placebo for both the
increase in FEV1and the AUC (Po0.001).
Heart rate
The adjusted mean treatment di¡erence between the
HFA pMDI and TH at each dose was well within the
pre-de¢ned equivalence limits. The largest di¡erence
(after 200mg of salbutamol) was2.4 bpm (95% CI5.6
to 0.9), and at the maximum dose (800mg) it was only
1.8 bpm (95% CI  5.2 to 1.7).There was no di¡erence
in AUC observed between devices (mean treatment dif-ference of1.0 bpmmin) [95% CI3.0 to1.1]), and no sig-
ni¢cant di¡erence between either device and placebo.
DISCUSSION
This study demonstrates clinical equivalence between
the pMDI and TH in children with asthma in terms of
the e¡ect of salbutamol on lung function (FEV1) or the
systemic parameter of heart rate. This is in accordance
with adult data (4) andwith other studieswhich have de-
monstrated equivalent e⁄cacy between the TH and
other DPIs such as the Diskus (5).
It has been claimed that only half the dose of drug is
required from aTHwhen compared to either a pMDI or
Diskhaler due to improved lung deposition (2,3,6,7). In
these studies, the drugs were not compared at micro-
gram equivalent doses, however, and they are contra-
dicted by in vitro studies which show a more accurate
dose of salbutamol and a higher ¢ne particle mass from
the pMDI than theTH (8). Furthermore, the e¡ective-
ness of a bronchodilator delivered from aTH ismore de-
pendent upon inspiratory £ow than from a pMDI (9),
exceptwhere inhalation from thepMDI is too fast.Taking
all this together, therefore, we do not believe that there
are anydi¡erences in the doserequired to achieve similar
relief between these two devices.
In conclusion, salbutamol delivery from a HFA pMDI
and TH is equivalent on a microgram basis in children
with asthma for both e⁄cacy and safety.
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